We are live on ! Find out more
JP Morgan Chase

JP Morgan Chase Portfolio holdings

AUM $1.81T
1-Year Est. Return 41.13%
 

JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.

This Fund
S&P 500
This Quarter Est. Return
-13.28%
1 Year Est. Return
+41.13%
3 Year Est. Return
+122.17%
5 Year Est. Return
+152.24%
10 Year Est. Return
+601.59%
AUM
$718B
AUM Growth
-$112B
Cap. Flow
+$11.7B
Cap. Flow %
1.63%
Top 10 Hldgs %
17.54%
Holding
7,270
New
568
Increased
2,561
Reduced
2,729
Closed
610

Sector Composition

Rank Sector Weight
1 Technology 15.03%
2 Healthcare 12.52%
3 Financials 10.5%
4 Consumer Discretionary 7.88%
5 Industrials 7.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CSCI
5951
DELISTED
COSCIENS Biopharma Inc. Common Stock
CSCI
$4K ﹤0.01%
228
-145
-39% -$3.63K
ACHL
5952
DELISTED
Achilles Therapeutics
ACHL
$4K ﹤0.01%
1,562
-3,043
-66% -$7.51K
LCW.WS
5953
DELISTED
Learn CW Investment Corporation Redeemable warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share
LCW.WS
0
CONXW
5954
DELISTED
CONX Corp. Warrant
CONXW
0
CYT
5955
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
$4K ﹤0.01%
1,418
-11,519
-89% -$29.4K
RAIN
5956
DELISTED
Rain Oncology Inc. Common Stock
RAIN
$4K ﹤0.01%
687
-8,928
-93% -$30.6K
CFIVW
5957
DELISTED
CF Acquisition Corp. IV Warrant
CFIVW
0
CCV.WS
5958
DELISTED
Churchill Capital Corp V Warrants, each exercisable for one share of Class A common stock at an exercise price of $11.50 per share
CCV.WS
0
FFHG
5959
DELISTED
Formula Folios Hedged Growth ETF
FFHG
$4K ﹤0.01%
+143
New +$4.7K
PRTK
5960
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$4K ﹤0.01%
2,063
-26,883
-93% -$58.7K
NYMX
5961
DELISTED
Nymox Pharmaceutical Corp
NYMX
$4K ﹤0.01%
9,261
-2,188
-19% -$2.01K
TRAQ.WS
5962
DELISTED
Trine II Acquisition Corp. Redeemable Warrants, each whole warrant exercisable for one Class A Ordinary Share at an exercise price of $11.50 per share
TRAQ.WS
0
OYST
5963
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
$4K ﹤0.01%
996
-7,288
-88% -$41.4K
FSSIW
5964
DELISTED
Fortistar Sustainable Solutions Corp. Warrant
FSSIW
0
LMACW
5965
DELISTED
Liberty Media Acquisition Corporation Warrants
LMACW
0
HNP
5966
DELISTED
Huaneng Power Intl, Inc.
HNP
$4K ﹤0.01%
200
-9
-4% -$169
CHIX
5967
DELISTED
Global X MSCI China Financials ETF
CHIX
$4K ﹤0.01%
330
AAAU icon
5968
Goldman Sachs Physical Gold ETF Shares
AAAU
$2.68B
$3K ﹤0.01%
164
-379
-70% -$7.05K
AKBA icon
5969
Akebia Therapeutics
AKBA
$248M
$3K ﹤0.01%
7,220
-4,250,978
-100% -$1.78M
AUBN icon
5970
Auburn National Bancorp
AUBN
$92.8M
$3K ﹤0.01%
114
BOLT icon
5971
Bolt Biotherapeutics
BOLT
$6.63M
$3K ﹤0.01%
72
-3,211
-98% -$125K
BROS icon
5972
PUT
Dutch Bros
BROS
$8.91B
$3K ﹤0.01%
100
CLLS
5973
Cellectis
CLLS
$296M
$3K ﹤0.01%
943
-1,466
-61% -$5.16K
COCP icon
5974
Cocrystal Pharma
COCP
$15.4M
$3K ﹤0.01%
689
-166
-19% -$884
CPNG icon
5975
PUT
Coupang
CPNG
$29.3B
$3K ﹤0.01%
200
-141,400
-100% -$1.93M

Similar funds

JP Morgan Chase's Q2 2022 Portfolio in Review

As of Q2 2022, JP Morgan Chase held 7,270 positions worth $718B, down 14% from $830B the previous quarter. Its ten largest holdings account for 18% of the portfolio.

JP Morgan Chase's Q2 2022 filing shows 568 new, 2,561 increased, 2,729 reduced and 610 closed positions. Its largest new stake was JPMorgan International Research Enhanced Equity ETF: 85,906,762 shares worth $4.15B. The largest sale was JPMorgan BetaBuilders Europe ETF, an estimated $4.61B.

By sector, the portfolio is most concentrated in Technology at 15% of assets, down from 16% a quarter earlier, followed by Healthcare and Financials.

  • JP Morgan Chase's largest Q2 2022 buy was JPMorgan International Research Enhanced Equity ETF: 85,906,762 shares worth $4.15B.
  • JP Morgan Chase added most to Microsoft in Q2 2022, an estimated $2.29B increase.
  • JP Morgan Chase's biggest Q2 2022 reduction was JPMorgan BetaBuilders Europe ETF, cutting an estimated $4.61B.
  • JP Morgan Chase fully exited Cerner Corp in Q2 2022, selling an estimated $608M.
  • JP Morgan Chase's ten largest holdings make up 18% of its $718B portfolio in Q2 2022.
  • JP Morgan Chase opened 568 new positions and closed 610 in Q2 2022.
  • JP Morgan Chase's portfolio value fell 14% quarter-over-quarter to $718B.

Based on JP Morgan Chase's 13F filing for Q2 2022, filed 11 Aug 2022.